Important US business magazine, Forbes, has crafted a list of the 100 most innovative companies on which the Danish medtech and pharma industry features prominently.
Coloplast makes it to number 12, and further down the list at number 70 diabetes giant Novo Nordisk is found.
The list is based on a so-called innovation premium, defined as “a measure of how much investors have bid up the stock price of a company above the value of its existing business based on expectations of future innovative results (new products, services and markets),” the magazine writes.
Moreover, companies on the list must have $10 billion in market capitalization, spend at least 2.5% of revenue on R&D and have seven years of public data.
In this regard, Coloplast and Novo scores an innovation premium of 46,5 % and 23,4 % respectively.
Life science fairs well
Generally speaking, the life science industry fairs well on Forbes’ innovation list. Two biotech companies, Alexion Pharmaceuticals (2) and Regeneron Pharmaceuticals (4), make it into the top 5.
Further down the list the medtech and pharmaceutical industries are represented by major corporations like Smith & Nephew (51), Valeant Pharmaceuticals (62), Covidien (67) og Mylan (90).
The only other Danish company on the list aside from Coloplast and Novo is Carlsberg, which slots in at 66.
Novo Nordisk tops global top 25 of biotechs
Novo among the 100 most valuable companies in the world
See the complete list from Forbes here.
Want to receive the latest news from Medwatch straight in your e-mail inbox? Sign up for our free english newsletter below.
Mere fra MedWatch
ALK forlader Tyrkiet efter mislykket lancering: "Hvis du får en gammel karklud for dine produkter, er det en dårlig forretning"
En række forhold gjorde det umuligt for ALK at etablere en fornuftig forretning i Tyrkiet, og den danske allergikoncern forlader derfor markedet, mens den også skærer salgsstyrken i Italien og Spanien ind til benet. Strategien er i stedet at satse hårdt på markeder med større potentiale, forklarer topchef Carsten Hellmann.
Zealand Pharmas underskud vokser i kvartal med frasalg
Zealand Pharma skruer ned forventningerne til indtægten fra nødpennen Zegalogue.
Genmab: Ny voldgift mod Janssen bygger på ligefremt spørgsmål
”Jeg synes, at der er tale om en meget mere simpel sag, end den første voldgift,” siger Jan van de Winkel, adm. direktør for Genmab, om den voldgiftssag, selskabet har indledt mod Janssen efter at have tabt tidligere strid.
Regioner tilbyder vaccination mod abekopper fra torsdag
Landets fem regioner skal informere risikogrupper og stå for vaccinationstilbud mod abekopper.
Novo Nordisk planlægger produktion af fedmemiddel på yderligere to fabrikker
Efter en lancering af fedmemidlet Wegovy, hvor Novo Nordisk slet ikke har kunnet følge med efterspørgslen, udvider medicinalselskabet næste år produktionen til yderligere to fabrikker.
Senior CMC Regulatory Manage 
Head of Regulatory Services Denmark 
Senior Manager, QA GCP/PV 
Lead Automationsingeniør ABB Sattline/ABB 800XA, AFRY 
Senior Clinical Trial Manager - Black Swans Exist 
IT QA Manager 
Director Regulatory Affairs 
Clinical Trial Manager - Black Swans Exist 
Open position for a Clinical Trial Manager to join our team at Nykode! 
Clinical Project Leader/ Sr. Clinical Trial Manager – make a difference and join our mission to bring our IL-22 lead program to patients 
Kvalitetskoordinator til Aseptisk Produktion, ALK 
GMP Compliance Consultant til Eltronic i Ballerup 
Tax Manager til PKA 
Supply Chain & Sourcing Manager 
Virksomhedsmæglere søges til landets førende virksomhedsmægler 
Lanceringskonsulent til Spillefilm 
Jurist til stillingen som advokatfuldmægtig